Why the study?
How do genetic polymorphisms influence platelet function, response to antiplatelet drugs, and clinical outcomes in patients with coronary artery disease?
How do genetic polymorphisms influence platelet function, response to antiplatelet drugs, and clinical outcomes in patients with coronary artery disease?
Genetic polymorphisms, particularly CYP2C19 loss-of-function alleles, significantly impair clopidogrel efficacy, highlighting the potential advantage of using prasugrel or ticagrelor for more predictable antiplatelet responses in coronary artery disease.
No takes yet. Share an insight, caveat, or question.
May support prasugrel or ticagrelor over clopidogrel in CYP2C19 LOF carriers; leaves open prospective trials of genotyping-guided therapy.
Tantry et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: